EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity

Paulina Szubińska-Bałaban, Aneta Klotzka, Katarzyna Ziółkowska, Patrycja Marciniak-Stępak, Julia Niedzielska, Federico Russo, Amro Abu Suleiman, Filip Glista, Angelika Kuczmarska, Ewelina Bukowska-Olech

Cardiovascular Toxicology · 2026

DOI: 10.1007/s12012-026-10191-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, 2026. Verfasst von Paulina Szubińska-Bałaban und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Diagnostics, Poznan University of Medical Sciences, Poznan, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cardiovascular Diseases, Neoplasms. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer therapy-related cardiovascular toxicity (CTR-CVT) is an umbrella term for myocardial, vascular, electrical, and inflammatory complications of cytotoxic, targeted, immune, and radiation-based therapies. Cancer therapy-related cardiac dysfunction (CTRCD) is used here more narrowly for treatment-related myocardial dysfunction, typically identified by changes in left ventricular ejection fraction, global longitudinal strain, and/or cardiac biomarkers. The pathophysiology of CTR-CVT is multifactorial, but the implicated pathways should not be interpreted as equally causal. The dominant initiating mechanism is therapy-specific - anthracycline injury is best supported by topoisomerase IIβ (TOP2B)-mediated DNA damage with secondary mitochondrial and redox injury; HER2-directed toxicity by disruption of NRG1-ERBB2/ERBB4 survival signalling; fluoropyrimidine toxicity by coronary vasomotor dysfunction; VEGF-pathway inhibition by endothelial dysfunction and hypertension; immune checkpoint inhibitor toxicity by loss of immune tolerance; and radiotherapy injury by endothelial and microvascular damage with progressive fibrosis. Mitochondrial dysfunction, oxidative stress, inflammation, calcium dysregulation, apoptosis, and ferroptosis frequently act as downstream or amplifying pathways, although the clinical relevance of several regulated cell-death mechanisms remains incompletely established. Genetic susceptibility may further modify risk, but the strength of evidence differs among reported loci. Replicated pharmacogenetic associations, rare variants in established cardiomyopathy genes, and preliminary candidate-gene findings should therefore be considered separately. Most available studies remain limited by small cohorts, heterogeneous phenotyping, ancestry imbalance, and incomplete external replication. This review critically evaluates the hierarchy and strength of mechanistic and genetic evidence and discusses the extent to which these findings can currently inform risk stratification, surveillance, prevention, and treatment in precision cardio-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCardiovascular DiseasesNeoplasmsCardiotoxicityHumansHeart Disease Risk FactorsGenetic Predisposition to DiseasePharmacogenomic VariantsAnimals

Stichwörter der Autor:innen

Cancer therapy-related cardiac dysfunctionCancer therapy-related cardiovascular toxicityCardio-oncologyGenetic susceptibilityPharmacogenomicsPrecision medicine

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Laboratory Diagnostics, Poznan University of Medical Sciences, Poznan, Poland.
  • Department of Cardiology, Poznań University of Medical Sciences, University Clinical Hospital, Poznań, Poland. aklotzka@ump.edu.pl.
  • Department of Pediatric Oncology Hematology and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
  • Poznan University of Medical Sciences, Student Scientific Society, Poznan, Poland.
  • Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Division of Cardiology, Sant'Andrea University Hospital, Rome, Italy.

Förderung

  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Zitieren

APA

Szubińska-Bałaban, P., Klotzka, A., Ziółkowska, K., Marciniak-Stępak, P., Niedzielska, J., Russo, F., Suleiman, A. A., Glista, F., Kuczmarska, A., & Bukowska-Olech, E. (2026). Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-026-10191-y

Vancouver

Szubińska-Bałaban P, Klotzka A, Ziółkowska K, Marciniak-Stępak P, Niedzielska J, Russo F, et al. Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity. Cardiovascular Toxicology. 2026. doi:10.1007/s12012-026-10191-y

BibTeX
@article{SzubiskaBaaban2026,
  author = {Szubińska-Bałaban, Paulina and Klotzka, Aneta and Ziółkowska, Katarzyna and Marciniak-Stępak, Patrycja and Niedzielska, Julia and Russo, Federico and Suleiman, Amro Abu and Glista, Filip and Kuczmarska, Angelika and Bukowska-Olech, Ewelina},
  title = {Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity},
  journal = {Cardiovascular Toxicology},
  year = {2026},
  doi = {10.1007/s12012-026-10191-y}
}
Kostenlos starten →